BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has announced that on April 12, the first patient of the Phase 3 clinical trial (SEER-2) of RGN-259, a novel treatment for neurotrophic keratitis (NK), has been enrolled and begun treatment.

Ventus Therapeutics, Inc. announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference, being held April 25-26 in Toronto.

Tonix Pharmaceuticals Holding Corp. today announced that it is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia and its Phase 2 PREVENTION study of TNX-1900 for chronic migraine.

Axsome Therapeutics, Inc. today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets.

atai Life Sciences announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).

Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.

Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in three presentations at the ARVO Annual Meeting, taking place April 23-27, 2023 in New Orleans.

Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types.

BioMech Holdings, LLC, which develops and distributes real-time motion analytics that quantify and improve patient outcomes in the healthcare, sports, wellness, and industrial sectors, is announcing the appointment of Athanassios Diplas, PhD to its board of directors.

Bold Therapeutics announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023.